AR061635A1 - Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos - Google Patents

Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos

Info

Publication number
AR061635A1
AR061635A1 ARP070102813A ARP070102813A AR061635A1 AR 061635 A1 AR061635 A1 AR 061635A1 AR P070102813 A ARP070102813 A AR P070102813A AR P070102813 A ARP070102813 A AR P070102813A AR 061635 A1 AR061635 A1 AR 061635A1
Authority
AR
Argentina
Prior art keywords
patient
treatment
patients
mild chronic
human patients
Prior art date
Application number
ARP070102813A
Other languages
English (en)
Inventor
Eldon R Smith
Anthony E Bolton
Arkady Mandel
Jay H Kleiman
David Elsley
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AR061635A1 publication Critical patent/AR061635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/369—Temperature treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para la profilaxis o tratamiento de pacientes que sufren de insuficiencia cardíaca cronica leve caracterizados porque se encuentran en uno o más de los siguientes grupos: pacientes con Clase II de CHF de acuerdo con la Asociacion del Corazon de Nueva York, pacientes que presentan un nivel sérico de CRP no mayor que 3,0 mg/mI, una fraccion de eyeccion de ventrículo izquierdo no menor que 23% y ningun infarto de miocardio previo. El método comprende administrar a dicho paciente una alícuota de la sangre del paciente extraída del paciente y tratada ex vivo con al menos un factor de estrés seleccionado del grupo formado por: un agente oxidante, una emision electromagnética y temperatura elevada.
ARP070102813A 2006-06-26 2007-06-25 Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos AR061635A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IE20060475 2006-06-26
CA2556233 2006-08-16
CA2558181 2006-08-31
CA2559600 2006-09-13

Publications (1)

Publication Number Publication Date
AR061635A1 true AR061635A1 (es) 2008-09-10

Family

ID=38845066

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102813A AR061635A1 (es) 2006-06-26 2007-06-25 Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos

Country Status (2)

Country Link
AR (1) AR061635A1 (es)
WO (1) WO2008000067A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003312A1 (en) * 2013-05-28 2016-04-13 Dana-Farber Cancer Institute, Inc. Bet inhibition therapy for heart disease
JP7414281B2 (ja) * 2017-08-08 2024-01-16 クイーンズランド ユニバーシティ オブ テクノロジー 初期心不全の診断方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029003A2 (en) * 1998-11-13 2000-05-25 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment

Also Published As

Publication number Publication date
WO2008000067A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
Hirai et al. Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization
AR071810A1 (es) Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
Heist et al. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment
PT1267897E (pt) Tratamento da insufuciencia cardiaca congestiva com sangue autologo previamente tratado
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
WO2006121532A3 (en) Treatment for heart disease
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR033510A1 (es) Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestiva
AR074107A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
KR20140032346A (ko) 암의 치료/전이의 억제
Yue et al. Cardiac support device (ASD) delivers bone marrow stem cells repetitively to epicardium has promising curative effects in advanced heart failure
AR074108A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
AR061635A1 (es) Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos
Krepska et al. The metabolic and endocrine response to trauma
BRPI0519931A2 (pt) métodos e composições para reduzir o dano microvascular derivado da isquemia
IT9086204A1 (it) Metodo per la cura dell'impotenza erettiva maschile
Nekooeian et al. Haemodynamic effects of a selective adenosine A2A receptor agonist, CGS 21680, in chronic heart failure in anaesthetized rats
Krepska et al. The metabolic and endocrine response to trauma
Colaiori et al. P2695 Safety of anticoagulation with uninterrupted NOAC vs interrupted NOAC in patients requiring an implantable cardiac device
Gandara Dabigatran was noninferior to warfarin for preventing recurrent venous thromboembolism
Jung et al. CHANGES IN BLOOD IONIZED MAGNESIUM AND CALCIUM IN EXPERIMENTAL CARDIOMYOPATHIES
Franklin The J-curve of cardiovascular disease risk and how it relates to isolated systolic hypertension
Kanic et al. OP-010 Does Intra Aortic Balloon Pump Implantation Influence Survival after Angioplasty of Left Main Coronary Artery in Patients Presented in Cardiogenic Shock
Taneva Is thrombolytic therapy effective in elderly patients?
Campa et al. Management of a rare ulcerated erythema nodosum in a patient affected by Crohn's disease and tuberculosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure